A Six-State Consortium Is Quietly Building Toward One Joint Ibogaine Drug Application
Michigan's HB 6020, a bipartisan bill from Reps. Jaime Greene and Matt McFall, would put $50 million of the state's opioid settlement money into FDA-supervised ibogaine trials for opioid use disorder, PTSD, and other conditions — the same settlement-funding playbook Louisiana adopted a few weeks ago. What makes it more than another state pilot: Michigan would join a consortium — states, drug manufacturers, health systems, and research universities — that's reportedly grown to six states in under a year, aiming to pool each state's trial data into a single, consolidated New Drug Application to the FDA. If that actually holds together, it's a genuinely novel end-run around the fact that no single state can get a drug approved on its own — states can generate the data, but the FDA still has to accept a joint submission built that way, which has no real precedent we're aware of. Worth tracking, not yet a sure thing.
Read at Michigan Advance / Reason Foundation